Advertisement

Pulmonary Rehabilitation in Restrictive Thoracic Disorders

  • Anne Holland
  • Nicolino Ambrosino
Chapter

Abstract

The interstitial lung diseases (ILDs) are a group of over 200 debilitating conditions characterised by lung inflammation and/or fibrosis. Idiopathic pulmonary fibrosis (IPF), the most common and lethal of the ILDs, accounts for approximately one-third of the ILDs and has a median survival of 3 years from diagnosis [1]. However, the clinical course varies widely and some patients with IPF will experience long periods of stability, whilst others will have frequent exacerbations or a rapid decline [2]. Interstitial lung disease may also occur due to an underlying systemic disease process, such as connective tissue disease or sarcoidosis, or an occupational exposure, such as asbestosis or silicosis. The incidence of ILD is increasing globally, largely due to a rise in the number of people who are diagnosed with IPF. Idiopathic pulmonary fibrosis is a disease of older people, with an estimated prevalence of 19 per 100,000 in those aged 55–64 years, rising to 88 per 100,000 in those 75 and over [3]. Consequently there will be more people living with IPF as the population ages in developed nations.

References

  1. 1.
    NICE. The diagnosis and management of suspected idiopathic pulmonary fibrosis: NICE clinical guideline, vol. 163. United Kingdom: National Institute for Health and Care Excellence; 2013.Google Scholar
  2. 2.
    Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Agusti AG, Roca J, Gea J, Wagner PD, Xaubet A, Rodriguez-Roisin R. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1991;143(2):219–25.CrossRefPubMedGoogle Scholar
  5. 5.
    Hansen JE, Wasserman K. Pathophysiology of activity limitation in patients with interstitial lung disease. Chest. 1996;109(6):1566–76.CrossRefPubMedGoogle Scholar
  6. 6.
    Swigris JJ, Stewart AL, Gould MK, Wilson SR. Patients’ perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes. 2005;3:61.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Cottin V, Cordier JF. Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J. 2012;40(3):519–21.CrossRefPubMedGoogle Scholar
  8. 8.
    Mendoza L, Gogali A, Shrikrishna D, Cavada G, Kemp SV, Natanek SA, Jackson AS, Polkey MI, Wells AU, Hopkinson NS. Quadriceps strength and endurance in fibrotic idiopathic interstitial pneumonia. Respirology. 2014;19(1):138–43.CrossRefPubMedGoogle Scholar
  9. 9.
    Spruit MA, Thomeer MJ, Gosselink R, Troosters T, Kasran A, Debrock AJ, Demedts MG, Decramer M. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax. 2005;60(1):32–8.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Marcellis RG, Lenssen AF, Elfferich MD, De Vries J, Kassim S, Foerster K, Drent M. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J. 2011;38(3):628–34.CrossRefPubMedGoogle Scholar
  11. 11.
    Madsen OR, Egsmose C, Hansen B, Sorensen OH. Soft tissue composition, quadriceps strength, bone quality and bone mass in rheumatoid arthritis. Clin Exp Rheumatol. 1998;16(1):27–32.PubMedGoogle Scholar
  12. 12.
    Watanabe, F., H. Taniguchi, K. Sakamoto, Y. Kondoh, T. Kimura, K. Kataoka, T. Ogawa, S. Arizono, O. Nishiyama, and Y. Hasegawa, Quadriceps weakness contributes to exercise capacity in nonspecific interstitial pneumonia.. Respir Med, 2013;107(4):622-628.Google Scholar
  13. 13.
    Mengshoel AM, Jokstad K, Bjerkhoel F. Associations between walking time, quadriceps muscle strength and cardiovascular capacity in patients with rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol. 2004;23(4):299–305.CrossRefPubMedGoogle Scholar
  14. 14.
    Kramer HR, Fontaine KR, Bathon JM, Giles JT. Muscle density in rheumatoid arthritis: associations with disease features and functional outcomes. Arthritis Rheum. 2012;64(8):2438–50.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Marighela TF, Genaro Pde S, Pinheiro MM, Szejnfeld VL, Kayser C. Risk factors for body composition abnormalities in systemic sclerosis. Clin Rheumatol. 2013;32(7):1037–44.CrossRefPubMedGoogle Scholar
  16. 16.
    Wallaert B, Monge E, Le Rouzic O, Wemeau-Stervinou L, Salleron J, Grosbois JM. Physical activity in daily life of patients with fibrotic idiopathic interstitial pneumonia. Chest. 2013;144(5):1652–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Bahmer T, Kirsten AM, Waschki B, Rabe KF, Magnussen H, Kirsten D, Gramm M, Hummler S, Brunnemer E, Kreuter M, Watz H. Clinical correlates of reduced physical activity in idiopathic pulmonary fibrosis. Respiration. 2016;91(6):497–502.CrossRefPubMedGoogle Scholar
  18. 18.
    Collard HR, Ward AJ, Lanes S, Cortney Hayflinger D, Rosenberg DM, Hunsche E. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ. 2012;15(5):829–35.CrossRefPubMedGoogle Scholar
  19. 19.
    King C, Nathan SD. Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. Curr Opin Pulm Med. 2013;19(5):466–73.CrossRefPubMedGoogle Scholar
  20. 20.
    King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2017;5(1):72–84.CrossRefPubMedGoogle Scholar
  21. 21.
    Holland AE, Fiore JF Jr, Bell EC, Goh N, Westall G, Symons K, Dowman L, Glaspole I. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology. 2014;19(8):1215–21.CrossRefPubMedGoogle Scholar
  22. 22.
    Ryerson CJ, Arean PA, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR. Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology. 2012;17(3):525–32.CrossRefPubMedGoogle Scholar
  23. 23.
    Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, Heussel CP, Warth A, Kolb M, Herth FJ. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One. 2016;11(3):e0151425.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, A.S. Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.CrossRefPubMedGoogle Scholar
  25. 25.
    Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR, Investigators IT. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.CrossRefPubMedGoogle Scholar
  26. 26.
    Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ. An Official ATS/ERS/JRS/ALAT Statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB, Wallace WA, Wells AU, Whyte MK, Wilsher ML. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(Suppl 5):v1–58.PubMedGoogle Scholar
  28. 28.
    Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, Hill K, Holland AE, Lareau SC, Man WD, Pitta F, Sewell L, Raskin J, Bourbeau J, Crouch R, Franssen FM, Casaburi R, Vercoulen JH, Vogiatzis I, Gosselink R, Clini EM, Effing TW, Maltais F, van der Palen J, Troosters T, Janssen DJ, Collins E, Garcia-Aymerich J, Brooks D, Fahy BF, Puhan MA, Hoogendoorn M, Garrod R, Schols AM, Carlin B, Benzo R, Meek P, Morgan M, Rutten-van Molken MP, Ries AL, Make B, Goldstein RS, Dowson CA, Brozek JL, Donner CF, Wouters EF. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13–64.CrossRefPubMedGoogle Scholar
  29. 29.
    Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2014;10:CD006322.Google Scholar
  30. 30.
    McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;2:CD003793.Google Scholar
  31. 31.
    Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63(6):549–54.CrossRefPubMedGoogle Scholar
  32. 32.
    Vainshelboim B, Oliveira J, Fox BD, Soreck Y, Fruchter O, Kramer MR. Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. Lung. 2015;193(3):345–54.CrossRefPubMedGoogle Scholar
  33. 33.
    Spruit MA, Pitta F, Garvey C, ZuWallack RL, Roberts CM, Collins EG, Goldstein R, McNamara R, Surpas P, Atsuyoshi K, Lopez-Campos JL, Vogiatzis I, Williams JE, Lareau S, Brooks D, Troosters T, Singh SJ, Hartl S, Clini EM, Wouters EF, E.R.S. Rehabilitation, C. Chronic, G. Physiotherapists Scientific, C. American Association of, R. Pulmonary, A.T.S.P.R. Assembly, and E.R.S. C.OPD Audit team. Differences in content and organisational aspects of pulmonary rehabilitation programmes. Eur Respir J. 2014;43(5):1326–37.CrossRefPubMedGoogle Scholar
  34. 34.
    Bolton CE, Bevan-Smith EF, Blakey JD, Crowe P, Elkin SL, Garrod R, Greening NJ, Heslop K, Hull JH, Man WD, Morgan MD, Proud D, Roberts CM, Sewell L, Singh SJ, Walker PP, Walmsley S, G. British Thoracic Society Pulmonary Rehabilitation Guideline Development, and C. British Thoracic Society Standards of Care. British Thoracic Society guideline on pulmonary rehabilitation in adults. Thorax. 2013;68(Suppl 2):ii1–30.CrossRefPubMedGoogle Scholar
  35. 35.
    Borg G. Psycho physical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377–81.CrossRefPubMedGoogle Scholar
  36. 36.
    Jenkins S, Cecins N. Six-minute walk test: observed adverse events and oxygen desaturation in a large cohort of patients with chronic lung disease. Intern Med J. 2011;41(5):416–22.CrossRefPubMedGoogle Scholar
  37. 37.
    Glaser S, Noga O, Koch B, Opitz CF, Schmidt B, Temmesfeld B, Dorr M, Ewert R, Schaper C. Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis. Respir Med. 2009;103(2):317–24.CrossRefPubMedGoogle Scholar
  38. 38.
    Pouwels-Fry S, Pouwels S, Fournier C, Duchemin A, Tillie-Leblond I, Le Tourneau T, Wallaert B. Effects of oxygen on exercise-induced increase of pulmonary arterial pressure in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25(2):133–9.PubMedGoogle Scholar
  39. 39.
    Holland AE, Fiore JF Jr, Goh N, Symons K, Dowman L, Westall G, Hazard A, Glaspole I. Be honest and help me prepare for the future: what people with interstitial lung disease want from education in pulmonary rehabilitation. Chron Respir Dis. 2015;12(2):93–101.CrossRefPubMedGoogle Scholar
  40. 40.
    Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, McCormack MC, Carlin BW, Sciurba FC, Pitta F, Wanger J, MacIntyre N, Kaminsky DA, Culver BH, Revill SM, Hernandes NA, Andrianopoulos V, Camillo CA, Mitchell KE, Lee AL, Hill CJ, Singh SJ. An official European Respiratory Society/American Thoracic Society Technical Standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1428–46.CrossRefPubMedGoogle Scholar
  41. 41.
    Ambrosino N, Carpenè N, Gherardi M. Chronic respiratory care in neuromuscular diseases for adults. Eur Respir J. 2009;34(2):444–51.CrossRefPubMedGoogle Scholar
  42. 42.
    Fiorenza D, Vitacca M, Bianchi L, Gabbrielli L, Ambrosino N. Lung function and disability in neuromuscular patients at first admission to a respiratory clinic. Respir Med. 2011;105(1):151–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C, DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy. Part 2: Implementation of multidisciplinary care. Lancet Neurol. 2010;9(2):177–89.CrossRefPubMedGoogle Scholar
  44. 44.
    Ambrosino N, Confalonieri M, Crescimanno G, Vianello A, Vitacca M. The role of respiratory Management of Pompe disease. Respir Med. 2013;107(8):1124–32.CrossRefPubMedGoogle Scholar
  45. 45.
    Vry J, Gramsch K, Rodger S, Thompson R, Steffensen BF, Rahbek J, Doerken S, Tassoni A, Beytía ML, Guergueltcheva V, Chamova T, Tournev I, Kostera-Pruszczyk A, Kaminska A, Lusakowska A, Mrazova L, Pavlovska L, Strenkova J, Vondráček P, Garami M, Karcagi V, Herczegfalvi Á, Bushby K, Lochmüller H, Kirschner J. European cross-sectional survey of current care practices for Duchenne Muscular Dystrophy reveals regional and age-dependent differences. J Neuromuscul Dis. 2016;3(4):517–27.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Bach JR. Noninvasive respiratory management of high level spinal cord injury. J Spinal Cord Med. 2012;35(2):72–80.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Dail C, Rodgers M, Guess V, Adkins HV. Glossopharyngeal breathing. Downey, CA: Rancho Los Amigos Department of Physical Therapy; 1979.Google Scholar
  48. 48.
    Webber B, Higgens J. Glossopharyngeal breathing: what, when and how? [video]. West Sussex, England: Aslan Studios Ltd., Holbrook, Horsham; 1999.Google Scholar
  49. 49.
    Strickland SL, Rubin BK, Drescher GS, Haas CF, O'Malley CA, Volsko TA, Branson RD, Hess DR, American Association for Respiratory Care, Irving, Texas. AARC Clinical Practice Guideline: effectiveness of nonpharmacologic airway clearance therapies in hospitalized patients. Respir Care. 2013;58(12):2187–93.CrossRefPubMedGoogle Scholar
  50. 50.
    McIlwaine M, Bradley J, Elborn JS, Moran F. Personalising airway clearance in chronic lung disease. Eur Respir Rev. 2017;26(143) doi:10.1183/16000617.0086-2016.
  51. 51.
    Gosselink R. Respiratory physiotherapy. In: Donner CF, Ambrosino N, Goldstein RS, editors. Pulmonary rehabilitation. London: Hodder Arnold; 2005. p. 186–94.CrossRefGoogle Scholar
  52. 52.
    Kang SW, Bach JR. Maximum insufflation capacity: vital capacity and cough flows in neuromuscular disease. Am J Phys Med Rehabil. 2000;79(3):222–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Chiou M, Bach JR, Jethani L, Gallagher MF. Active lung volume recruitment to preserve vital capacity in Duchenne Muscular Distrophy. J Rehabil Med. 2017;49(1):49–53.CrossRefPubMedGoogle Scholar
  54. 54.
    Suri P, Burns SP, Bach JR. Pneumothorax associated with mechanical insufflation-exsufflation and related factors. Am J Phys Med Rehabil. 2008;87(11):951–5.CrossRefPubMedGoogle Scholar
  55. 55.
    Venturelli E, Crisafulli E, DeBiase A, Righi D, Berrighi D, Cavicchioli PP, Vagheggini G, Dabrosca F, Balbi B, Paneroni M, Bianchi L, Vitacca M, Galimberti V, Zaurino M, Schiavoni G, Iattoni A, Ambrosino N, Clini EM. Efficacy of temporary positive expiratory pressure (TPEP) in patients with lung diseases and chronic mucus hypersecretion. The UNIKO® project. Clin Rehabil. 2013;27(4):336–46.CrossRefPubMedGoogle Scholar
  56. 56.
    Guarracino F, Bertini P, Bortolotti U, Stefani M, Ambrosino N. Flexible bronchoscopy during mechanical ventilation in the prone position to treat acute lung injury. Rev Port Pneumol. 2013;19(1):42–4.CrossRefPubMedGoogle Scholar
  57. 57.
    Strickland SL, Rubin BK, Haas CF, Volsko TA, Drescher GS, O'Malley CA. AARC Clinical Practice Guideline: effectiveness of pharmacologic airway clearance therapies in hospitalized patients. Respir Care. 2015;60(7):1071–7.CrossRefPubMedGoogle Scholar
  58. 58.
    Katz SL, Barrowman N, Monsour A, Su S, Hoey L, McKim D. Long-term effects of lung volume recruitment on maximal inspiratory capacity and vital capacity in Duchenne muscular dystrophy. Ann Am Thorac Soc. 2016;13(2):217–22.PubMedGoogle Scholar
  59. 59.
    Bach JR. Mechanical insufflation-exsufflation. Comparison of peak expiratory flows with manually assisted and unassisted coughing techniques. Chest. 1993;104(5):1553–62.CrossRefPubMedGoogle Scholar
  60. 60.
    Vianello A, Corrado A, Arcaro G, Gallan F, Ori C, Minuzzo M, Bevilacqua M. Mechanical insufflation exsufflation improves outcomes for neuromuscular disease patients with respiratory tract infections. Am J Phys Med Rehabil. 2005;84(2):83–8.CrossRefPubMedGoogle Scholar
  61. 61.
    Lee JW, Won YH, Kim DH, Choi WA, Bach JR, Kim DJ, Kang SW. Pulmonary rehabilitation to decrease perioperative risks of spinal fusion for patients with neuromuscular scoliosis and low vital capacity. Eur J Phys Rehabil Med. 2016;52(1):28–35.PubMedGoogle Scholar
  62. 62.
    Goncalves MR, Honrado T, Winck JC, Paiva JA. Effects of mechanical insufflation-exsufflation in preventing respiratory failure after extubation: a randomized controlled trial. Crit Care. 2012;16(2):R48.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Bach JR, Goncalves MR, Hamdani I, Winck JC. Extubation of patients with neuromuscular weakness: a new management paradigm. Chest. 2010;137(5):1033–9.CrossRefPubMedGoogle Scholar
  64. 64.
    Auger C, Hernando V, Galmiche H. Use of mechanical insufflation-exsufflation devices for airway clearance in subjects with neuromuscular disease. Respir Care. 2017;62(2):236–45.CrossRefPubMedGoogle Scholar
  65. 65.
    Narayanaswami P, Weiss M, Selcen D, David W, Raynor E, Carter G, Wicklund M, Barohn RJ, Ensrud E, Griggs RC, Gronseth G, Amato AA. Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal dystrophies: report of the guideline development subcommittee of the American Academy of Neurology and the practice issues review panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology. 2014;83(16):1453–63.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Boentert M, Prigent H, Várdi K, Jones HN, Mellies U, Simonds AK, Wenninger S, Barrot Cortés E, Confalonieri M. Practical recommendations for diagnosis and management of respiratory muscle weakness in late-onset Pompe Disease. Int J Mol Sci. 2016;17(10.) pii: E1735Google Scholar
  67. 67.
    Aslan GK, Gurses HN, Issever H, Kiyan E. Effects of respiratory muscle training on pulmonary functions in patients with slowly progressive neuromuscular disease: a randomized controlled trial. Clin Rehabil. 2014;28(6):573–81.CrossRefPubMedGoogle Scholar
  68. 68.
    Eidenberger M, Nowotny S. Inspiratory muscle training in patients with amyotrophic lateral sclerosis: a systematic review. NeuroRehabilitation. 2014;35(3):349–61.PubMedGoogle Scholar
  69. 69.
    Garuti G, Bagatti S, Verucchi E, Massobrio M, Spagnolatti L, Vezzani G, Lusuardi M. Pulmonary rehabilitation at home guided by telemonitoring and access to healthcare facilities for respiratory complications in patients with neuromuscular disease. Eur J Phys Rehabil Med. 2013;49(1):51–7.PubMedGoogle Scholar
  70. 70.
    Ambrosino N, Vitacca M, Dreher M, Isetta V, Montserrat JM, Tonia T, Turchetti G, Winck JC, Burgos F, Kampelmacher M, Vagheggini G, ERS Tele-Monitoring of Ventilator-Dependent Patients Task Force. Tele-monitoring of ventilator-dependent patients: a European Respiratory Society Statement. Eur Respir J. 2016;48(3):648–63.CrossRefPubMedGoogle Scholar
  71. 71.
    Ambrosino N, Makhabah DN. Tele-medicine: a new promised land, just to save resources? Eur Respir J. 2017;49:1700410.Google Scholar
  72. 72.
    Escarrabil J, Vianello A, Farrero E, Ambrosino N, Martínez LJ, Vitacca M. Place of death in patients with amyotrophic lateral sclerosis. Rev Port Pneumol. 2014;20(4):188–93.CrossRefGoogle Scholar
  73. 73.
    Lloyd-Owen SJ, Donaldson GC, Ambrosino N, Escarabill J, Farre R, Fauroux B, Robert D, Schoenhofer B, Simonds AK, Wedzicha JA. Patterns of home mechanical ventilation use in Europe: results from the Eurovent survey. Eur Respir J. 2005;25(6):1025–31.CrossRefPubMedGoogle Scholar
  74. 74.
    Vitacca M, Grassi M, Barbano L, Galavotti G, Sturani C, Vianello A, Zanotti E, Ballerin L, Potena A, Scala R, Peratoner A, Ceriana P, Di Buono L, Clini E, Ambrosino N, Hill N, Nava S. Last 3 months of life in home-ventilated patients: the family perception. Eur Respir J. 2010;35(5):1064–71.CrossRefPubMedGoogle Scholar
  75. 75.
    Di Paolo M, Evangelisti L, Ambrosino N. Unexpected death of a ventilator-dependent ALS patient. Rev Port Pneumol. 2013;19(4):175–8.CrossRefPubMedGoogle Scholar
  76. 76.
    Winck J, Camacho R, Ambrosino N. Multidisciplinary rehabilitation in ventilator-dependent patients: call for action in specialized inpatients facilities. Rev Port Pneumol (2006). 2015; doi:10.1016/j.rppnen.2015.03.005.
  77. 77.
    Barawid E, Covarrubias N, Tribuzio B, Liao S. The benefits of rehabilitation for palliative care patients. Am J Hosp Palliat Care. 2015;32(1):34–43.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Alfred Health and Institute for Breathing and Sleep, La Trobe UniversityMelbourneAustralia
  2. 2.Research Consultant, Pulmonary and Respiratory Medicine Department, Faculty of MedicineUniversitas Sebelas MaretSurakartaIndonesia
  3. 3.Istituti Clinici Scientifici Maugeri, Scientific Institute of MontescanoMontescanoItaly

Personalised recommendations